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ABSTRACT 
Objective: Smoking is the largest preventable cause of death and disability in the UK and remains 
pervasive in people with mental disorders and in general hospital patients. We aimed to quantify the 
prevalence of mental disorders and smoking, examining associations between mental disorders and 
smoking in patients with chronic physical conditions.  
Method: Data were collected via routine screening systems implemented across two London NHS 
Foundation Trusts. The prevalence of mental disorder, current smoking, nicotine dependence and 
wanting help with quitting smoking were quantified, and the relationships between mental disorder 
and smoking were examined, adjusting for age, gender and physical illness, with multiple regression 
models.  
Results: A total of 7,878 patients were screened; 23.2% screened positive for probable major 
depressive disorder, and 18.5% for probable generalised anxiety disorder. Overall, 31.4% and 
29.2% of patients with probable major depressive disorder or generalised anxiety disorder 
respectively were current smokers. Probable major depression and generalised anxiety disorder 
were associated with 93% and 44% increased odds of being a current smoker respectively. Patients 
with depressive disorder also reported higher levels of nicotine dependence, and the presence of 
common mental disorder was not associated with odds of wanting help with quitting smoking.  
Conclusion: Common mental disorder in patients with chronic physical health conditions is a risk 
factor for markedly increased smoking prevalence and nicotine dependence. A general hospital 
encounter represents an opportunity to help patients who may benefit from such interventions. 
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1.0 INTRODUCTION 
Smoking is the largest preventable cause of disability and death in the UK, and one of the most cost-
effective methods of maintaining health and prolonging life is to encourage smoking cessation.[1] 
The prevalence of smoking continues to decline in the UK, having already dropped from 45% of all 
adults in 1974, to 19% of adults in 2013.[2] However this decline in smoking behaviour has not been 
mirrored amongst people with mental disorders: an estimated 37% of people with depression are 
current smokers, and people with a mental disorder smoke approximately 42% of all the cigarettes 
smoked by the English general population.[3] Similarly, data from a nationally representative US 
sample reports a slower decline in smoking rates between 2004-2011 in people with mental disorder 
in comparison to people without mental disorder. [4] The overlap between mental and physical 
illness is substantial, with 30% of the UK population having a long-term physical illness,[5] and 30% 
of those also have a comorbid mental disorder.[6] Smoking in general hospital patients is prevalent, 
with 1.1 million smokers treated per year in English hospitals, representing 2.6 million episodes of 
care.[7] 
There are several effective methods of enhancing smoking cessation, including behavioural support 
and medication, which are offered free of charge within the National Health Service (NHS).[8] 
Evidence suggests that smoking cessation interventions can be effective are no less effective in 
smokers with common mental disorders. [9] A recent multicentre randomised controlled trial 
examining the impact of varenicline on smoking cessation rates in adults with stable current or past 
major depressive disorder has shown increased cessation with no adverse effects on symptoms of 
depression or anxiety. [9] Furthermore, staged intervention incorporating motivational feedback and 
psychological counselling can be effective for enhancing cessation in mental health outpatients. [10] 
Analysis of a randomised controlled trial examining the impact of counselling combined with Nicotine 
Replacement Therapy has also demonstrated no adverse mental health outcomes after quitting 
smoking in patients with clinical depression [11] and meta-analysis evidence suggests that cessation 
may reduce symptoms of depression and anxiety [12]. 
 4 
 
Despite the range of effective interventions available, smoking cessation rates in people with mental 
disorders are much lower than in the general population.[13-14] Depressed smokers are as willing 
to attempt cessation as non-depressed smokers, and severity of depression and history of 
depression recurrence are not associated with willingness to quit.[15-16]   However smokers with 
mental disorders are less likely to be offered smoking cessation support and are frequently excluded 
from smoking cessation trials.[17] One hypothesis for this may be that healthcare professionals may 
perceive depressed smokers to be unwilling to quit, less able to quit, or have concerns that quitting 
may exacerbate symptoms of depression.[18] However an unsuccessful quit attempt has been 
previously associated with increased odds of experiencing lifetime depression and anxiety 
compared to non-quitters, and increased prevalence of current depression [19]. 
The frequency with which many patients with chronic physical conditions are required to attend 
hospital appointments means that a hospital encounter may be a potentially valuable intervention 
point. Experiencing a health scare, such as diagnosis of illness or acute health event, may provide 
a teachable moment to facilitate behaviour change, and result in smokers being more likely to 
engage in cessation interventions.[20] Smoking cessation in patients with chronic physical 
conditions is likely to be highly beneficial for improving health outcomes. However, as yet there has 
been limited assessment of smoking and mental health within the context of physical illness.  
To the best of our knowledge, this will be the first paper to examine the relationships between mental 
and physical comorbidity and smoking, using screening data collected as part of routine clinical 
practice, representing a large heterogeneous secondary care sample. We aimed: 1) to describe the 
prevalence of mental disorders, current smoking status, and level of nicotine dependence in patients 
with chronic physical conditions; 2) to examine the associations between mental disorders and 
smoking prevalence and level of nicotine dependence in patients with chronic physical health 
conditions; and 3) to establish the association between mental health status and wanting help with 
quitting smoking in patients with chronic physical conditions. 
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2.0 METHOD 
2.1 Procedure 
Data were collected via the Integrating Mental and Physical Healthcare: Research, Training and 
Services (IMPARTS) screening interface. [21] IMPARTS was designed to integrate the detection 
and management of mental disorders within physical healthcare environments; the web-based 
screening platform also facilitates the routine collection of patient-reported outcomes, and health 
behaviours, including smoking. IMPARTS provides this screening interface within a novel model of 
service delivery allowing physical health specialties to routinely monitor pertinent elements of mental 
and physical health, and health behaviours in real-time, and provide appropriate, tailored support 
and recommendations for onward referral. IMPARTS has been implemented within King’s Health 
Partners (KHP), an Academic Health Science Centre in London, including a university (King’s 
College London), two acute NHS Hospital Trusts (King’s College Hospital (KCH) NHS Foundation 
Trust and Guy’s and St. Thomas’ (GSTT) NHS Foundation Trust), and an NHS Mental Health Trust 
(South London and the Maudsley NHS Foundation Trust).  
Patients attending general hospital appointments were given an information sheet inviting them to 
complete a series of questionnaires whilst waiting for their appointment. The information sheet 
informed them that the information is being collected as part of their routine care at the hospital, and 
that the information they provide is confidential and will be dealt with anonymously if used for audit 
or research purposes. Informed consent is not required for these purposes. Patients completed a 
series of measures chosen by the clinical team and specific to their physical condition on an iPad. 
The data were then transferred immediately to their Electronic Patient Record (EPR), allowing the 
clinicians to review the results in real-time, facilitating discussion during the appointment. Positive 
screens for probable major depressive disorder (pMDD), suicidal ideation or probable generalised 
anxiety disorder (pGAD) were flagged, with appropriate care pathways and risk assessment 
procedures provided. The system has been designed to be fully embedded in clinical care, with 
existing staff taking responsibility for implementing screening, and managing the screening results, 
supported by ongoing training from the IMPARTS team when required.   
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Twenty-one clinical services across 3 acute hospital sites were utilising the IMPARTS screening 
system at the time of these analyses. These represent services that have identified the need to 
standardise their collection of patient-reported outcomes, and approached the IMPARTS team 
requesting the implementation of routine screening in their clinics. These services range from large 
rheumatology and dermatology clinics, seeing hundreds of patients per week, to smaller services 
seeing less common physical conditions such as neuroendocrine tumours and endocarditis. The 
heterogeneity in services has resulted in vastly differing sample sizes for each chronic physical 
condition. For the purposes of this study, a pragmatic decision was made to include only services 
contributing data from over 100 unique patients between February 2011 (when the first service 
implemented IMPARTS) until June 2015. Patients were asked to complete questionnaires via the 
IMPARTS screening system at every hospital visit, however smoking data is only collected at one 
hospital visit per year. This analysis focused on the data collected at each patient’s first screening 
encounter. Although primarily a method of collecting patient-reported outcomes for clinical care, 
IMPARTS has received ethical approval for anonymised data collected via the screening interface 
to be used for research purposes (REC: 12-SC-0422).  
2.2 Setting 
Data from 10 services were used in the current analysis. Pilot data collected from Rheumatology, 
Limb Reconstruction and Dermatology services show that uptake of screening was high, with the 
majority of patients attending appointments being successfully screened (62.5%-98.2%) and only a 
small proportion of patients declining screening (0.6%-5.1%).[21] The services contributing data to 
the current analysis were: adult congenital heart disease (ACHD); dermatology (a tertiary service 
comprising patients with hidradenitis suppurativa, psoriasis or eczema); dialysis (representing 
patients on haemodialysis in three satellite units); limb reconstruction; liver transition (adolescents 
or young adults with chronic liver disease or liver transplant); musculoskeletal physiotherapy; chronic 
pain (an interdisciplinary unit delivering intensive outpatient or residential treatments); rheumatology 
(representing the full range of rheumatic diseases); stroke (hyper-acute stroke outpatients); and 
teenage and young adult (TYA) cancer.  
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2.3 Measures 
The IMPARTS screening interface allows for a flexible and tailored battery of measures to be 
implemented in different services, depending on the physical condition. Given that the primary 
purpose of data collection via IMPARTS is for routine clinical care, the measures chosen are those 
of most clinical utility within the clinic setting. As such, they are necessarily brief, and the mental 
health questionnaires are limited to assessing common mental health problems (depression and 
anxiety). Although the questionnaire sets used in each service differ, depression, anxiety, and 
smoking are measured using the same outcome measures across all services, except for anxiety 
which was not measured in the pain service. Given the heterogeneity of the data collected for each 
physical condition, analysis was restricted to variables common to all physical conditions: age, 
gender, depression, anxiety, and smoking.  
2.3.1 Depression 
Depression was measured using the 9-item Patient Health Questionnaire (PHQ9; [22] which has 
been recommended by the National Institute for Health and Care Excellence (NICE) for use in adult 
patients with chronic physical health problems.[23] The PHQ9 has good sensitivity and specificity 
for identifying major depressive disorder in patients with physical health conditions,[24] and has good 
test-retest reliability. [25] To identify the presence of probable major depressive disorder (pMDD), 
the validated categorical algorithm was used. [24] pMDD was defined as scoring “more than half the 
days” or “nearly every day” within the last two weeks on at least one of the first two items of the 
PHQ-9 (low mood and a loss of interest in activities), and on at least five out of all nine symptoms. 
Item nine of the PHQ9 (“Thoughts that you would be better off dead or of hurting yourself in some 
way”) was used to assess suicidal ideation, with patients identifying this symptom more than half the 
days in the past two weeks categorised as experiencing suicidal ideation contributing towards pMDD 
diagnosis if present at all. [24] 
 Patients scoring “not at all “or “several days” to all questions were categorised as having “No 
symptoms”, and patients reporting symptoms “more than half the days” or “nearly every day” but not 
reaching criteria for pMDD were coded as having “some symptoms”. This resulted in a final 
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depression independent variable coded with the following categories: 0 “No symptoms”; 1 “Some 
symptoms”; 2 “pMDD”.  
2.3.2 Anxiety 
Anxiety was assessed using the 7-item Generalised Anxiety Disorder (GAD7) questionnaire. [26] 
This measure has good reliability, sensitivity and specificity, as well as criterion, construct, factorial 
and procedural validity. [26] A score of 10 or more on the GAD7 identified cases of probable 
Generalised Anxiety Disorder (pGAD); scores ranging 5-9 indicated the presence of some anxiety 
symptoms. This results in a final anxiety independent variable coded with the following categories: 
0 “no symptoms” (scores <5); 1 “some symptoms” (scores 5-9); and 2 “pGAD” (scores ≥10).  
2.3.3 Smoking 
Prevalence of current smoking was assessed by asking patients if they currently smoke (providing 
yes or no answers). The severity of nicotine dependence for self-reported smokers was assessed 
using the Heaviness of Smoking Index (HSI).[27] This two item measure asks how many cigarettes, 
cigars or rollups they smoke per day (cigarettes per day; CPD); and how soon after waking up they 
smoke their first cigarette, allowing one of the following categories to be selected: within 5 minutes; 
6-30 minutes; 31-60 minutes; after 60 minutes (time to first cigarette; TTFC). CPD and TTFC can be 
combined to form the HSI through scoring CPD from 0 (10 or less) to 3 (31 or more), scoring TTFC 
from 0 (after 60 minutes) to 3 (within 5 minutes), and summing the total. This results in a score from 
0-6, with higher scores indicating heavier smoking levels. Since March 2014 current smokers were 
also asked if they wanted help with quitting smoking using a one-item question (“Would you like help 
with quitting smoking”) with “Yes/No” answer options. This question was added in later to coincide 
with the hospitals introducing new smoking cessation services, with the aim of identifying patients 
who would be willing to receive onward referral to smoking cessation services. 
2.4 Statistical Analysis 
Percentages, means and standard deviations were used to describe sample demographics and 
prevalence of psychological morbidity and smoking and level of nicotine dependence. The IMPARTS 
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system does not allow patients to complete a questionnaire leaving any answers omitted, therefore 
there were no missing data. All analyses were run using Stata v.14.  
Aim 1: Describing the prevalence of mental disorder, current smoking status and level of 
nicotine dependence in patients with chronic physical health conditions. 
Prevalence of mental disorders and smoking were expressed as percentages, with 95% confidence 
intervals (95%CI). Descriptions of the smoking characteristics of patients with and without pMDD or 
pGAD were compared using Chi-square tests for categorical data (current smoking status, wanting 
help with quitting) and analysis of variance (ANOVA) for continuous data (nicotine dependence).  
Aim 2: The association between mental disorder and smoking prevalence and level of 
nicotine dependence in patients with chronic physical health conditions.  
A multiple logistic regression model assessed the relationship between the independent variables 
(depression and anxiety) and dependent variable (current smoking status). Suicidal ideation, 
gender, age and physical condition were also included as covariates. As anxiety was not measured 
in the pain service, the model was created in two stages: 1) all independent variables and covariates 
were entered into the model simultaneously to report the associations between depression, age, 
gender and suicidal ideation and odds of being a current smoker; 2) the model was re-run excluding 
physical condition as a covariate to report the association between anxiety and odds of being a 
current smoker, adjusting for age, gender, depression and suicidal ideation. Tests of linear trend 
were included to provide a p-value for a linear association between increased depression and 
anxiety severity and odds of being a current smoker.  
The same variable entry method and adjustment for covariates was used in a multivariate linear 
regression model examining the linear dependent variable: nicotine dependence. Tests of linear 
trend were included to provide a p-value for a linear association between increased depression and 
anxiety severity and level of nicotine dependence.  
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Aim 3: the association between mental health status and wanting help with quitting smoking 
in patients with chronic physical conditions.  
A multiple logistic regression model assessed the relationship between the independent variables 
(depression and anxiety) and dependent variable (wanting help with quitting). Suicidal ideation, 
gender, age and physical condition were also included as covariates. The same variable entry 
method and adjustment for covariates were used, as described for aim 2. Tests of linear trend were 
included to provide a p-value for linear association between increased depression and anxiety 
severity and odds of wanting help with quitting smoking. 
3.0 RESULTS 
3.1 Sample Statistics 
The study sample is described in Table 1. In total, data from 7878 outpatients were included, 
representing 10 chronic physical conditions. The overall mean age was 44.8 years (SD=16.2), and 
57.8% of the overall sample were female. Mean ages and proportion of female patients varied across 
the physical conditions, in accordance with expected varying patient demographics: the mean ages 
in services seeing exclusively young adults (liver transition and TYA cancer) were 18.1 and 21.7 
years respectively; conditions typically affecting working age adults had mean ages of 43.9, 44.8, 
43.8, 45.8, and 50.0 years (dermatology, limb reconstruction, MSK physiotherapy, pain and 
rheumatology respectively).  
3.2 The prevalence of common mental disorders and smoking 
The combined prevalence of pMDD was 23.2% (95%CI: 22.2%-24.1%), with 6.1% (95%CI: 5.6%-
6.6%) of patients experiencing suicidal ideation and the prevalence of pGAD across the physical 
conditions was 18.5% (95%CI: 17.6%-19.4%) (Table 1). The prevalence of current smoking overall 
was 19.6% (95%CI: 18.7%-20.5%) and the overall mean HSI was 1.7 (SD=1.5). Overall, 37.8% 
(95%CI: 34.9%-40.9%) of current smokers wanted help with quitting smoking.  
A significantly larger percentage of patients with pMDD were current smokers; 31.4%, in comparison 
to only 20% of patients with some symptoms, and 15.2% of patients with no depression symptoms 
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(Chi2 = 223.1, d.f. = 2, p<0.001). Smokers with pMDD also reported a HSI score of 2.4 (SD=1.2), in 
comparison to 2.2 (SD=1.1) and 2.1 (SD=1.2) in patients with some and no symptoms respectively 
(F(2,1202) = 8.1, p<0.001). Also, 43.4% of smokers with pMDD wanted help with quitting, in 
comparison to only 37.9% of smokers with some depressive symptoms and 34.2% of smokers with 
no depression (Chi2 = 7.5, d.f. = 2, p=0.02). Similarly, a significantly larger percentage of patients 
with pGAD were current smokers; 29.2%, in comparison to 15% of patients with some anxiety 
symptoms, and 15.6% of patients with no anxiety symptoms (Chi2 = 128.2, d.f. = 2, p<0.001). 
Smokers with pGAD also reported a HSI score of 2.3 (SD=1.2), in comparison to 2.2 (SD=1.1) and 
2.1 (SD=1.1) in patients with some and no anxiety symptoms respectively (F(2,960) = 1.7, p<0.01). 
Also, 43.1% of smokers with pGAD wanted help with quitting smoking, in comparison to only 40.5% 
of smokers with some symptoms and 33.5% of smokers with no anxiety (Chi2 = 7.06, d.f. = 2, 
p=0.03).  
>>>TABLE 1<<< 
3.3 The associations between common mental disorders and smoking prevalence 
Table 2 shows the results of a multiple logistic regression analysis examining the associations 
between depression, anxiety and suicidal ideation and current smoking status, adjusting for age, 
gender and physical condition.  
In comparison to patients with no symptoms of depression, patients with some symptoms had 46% 
greater odds of being a current smoker and patients with pMDD had 93% higher odds of being a 
current smoker. This was statistically significant in a test of linear trend (OR = 1.93, SE= 0.21 
p<0.001; Table 2). Patients with pGAD had 44% increased odds of being a current smoker, in 
comparison to patients with no anxiety symptoms, in a test of linear trend (p=0.001; Table 2).  
>>>TABLE 2<<< 
3.4 The association between common mental disorders and nicotine dependence 
Table 3 shows the results of a multiple linear regression analysis examining the associations 
between depression, anxiety and suicidal ideation and nicotine dependence, adjusting for age, 
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gender and physical condition. Patients with some symptoms of depression and pMDD had higher 
HSI scores, which was statistically significant in a test of linear trend (p<0.001). There were no 
significant differences in nicotine dependence between patients with and without suicidal ideation or 
between anxiety categories.  
>>>TABLE 3<<< 
3.5 The association between mental health and wanting help to quit smoking 
Measurement of wanting help with quitting smoking was added in March 2014, making this data 
available only for the 1015 most recently screened smokers. Table 4 shows the results of a 
multivariate logistic regression model assessing the association between depression, anxiety and 
suicidal ideation and odds of wanting help with quitting smoking, adjusting for age, gender, 
depression category, suicidal ideation and anxiety category, adjusted for chronic physical condition.  
Neither depression nor anxiety were associated with odds of wanting help with quitting smoking. 
>>>TABLE 4<<< 
4.0 DISCUSSION 
This paper highlights the potential of embedding routine patient reported outcomes into clinical 
practice, promoting research as an outgrowth of patient care. Using data collected as part of routine 
care fosters research and audit with minimal intrusiveness for patients. We have identified that 
comorbid depression and anxiety are associated with increased smoking prevalence in patients with 
chronic physical health conditions: 31.4% of patients with comorbid depression and 29.2% of 
patients with comorbid anxiety are self-reported current smokers. These estimates are substantially 
higher than the 19% smoking prevalence reported in the UK general population. [2] Patients with 
comorbid mental disorder also demonstrated higher levels of nicotine dependence, and were no less 
likely to want help with quitting smoking than patients without psychological comorbidity. Indeed, 
patients with suicidal ideation reported increased odds of wanting help with quitting smoking.  
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Despite reporting a higher level of smoking prevalence than the general population, [2] we have 
identified a lower prevalence estimate than has been previously reported in a general hospital 
sample. [7] This could be for several reasons: it may reflect our focus on long-term physical 
conditions managed in secondary care. An unselected hospital sample would be expected to have 
a larger proportion of chronic lung diseases and ischaemic heart disease patients, in whom smoking 
prevalence would be predictably higher [28]. Additionally, self-report smoking status may 
underestimate actual smoking, [29] particularly in smokers at risk of cardiovascular disease. [30] 
This under-reporting of smoking may be exacerbated in the current context. Patients are attending 
a hospital for a physical health condition; they may have a long-standing relationship with their 
healthcare professional (HCP) and they know their HCP will be viewing their screening results. [21] 
Patients who smoke may have already been encouraged to quit by their HCP, or may not want to 
reveal that they are still smoking.    
Services seeing exclusively younger patients, or patients usually diagnosed during childhood show 
the lowest smoking prevalence (liver transition 12.4%, ACHD 10.6% and TYA oncology 12.8%). This 
finding is at odds with the wider literature. There is evidence highlighting increased engagement with 
health risk behaviours, such as smoking, antisocial behaviour and cannabis use in adolescents with 
physical conditions or disability. [31] Future research specifically examining this question may be 
beneficial, to improve understanding of the complex relationship between health and behaviour in 
childhood and adolescence.  
The notably high proportion of patients reporting wanting help with quitting smoking (43.4% of 
depressed patients and 43.1% of anxious patients) indicates that patients may find a hospital 
encounter useful for obtaining support with quitting smoking. This highlights the need for integrated 
smoking cessation support within general hospital environments. Early identification of smoking 
status and nicotine dependence is quick, simple, and is crucial for timely and appropriate 
intervention. A hospital encounter may act as an essential point of contact for smokers with mental 
and physical comorbidity, who may benefit the most from prompt smoking cessation support. Meta-
analysis evidence has found a significant association between smoking cessation and reduced 
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symptoms of depression and anxiety.[12] Both smoking and common mental disorder are related to 
worsened long-term physical health outcomes, [32] reduced quality of life [33] and increased 
mortality [34] in chronic diseases, therefore encouraging smoking cessation as part of routine clinical 
care serves a dual purpose in improving physical and mental health outcomes, and reducing risk of 
premature mortality. [35-37]  
The collection of patient reported outcomes via tablet devices lends itself to the delivery of e-
interventions. Recently, patients reporting wanting help with quitting smoking via IMPARTS have 
been asked if they would like to sign-up to a text-based smoking cessation intervention: 
Txt2Stop.[38] If they consent, they are automatically sent a text message with details on how to sign 
up. The extent to which comorbidity and embedded screening can predict uptake of, adherence to, 
and outcomes from this form of intervention need to be assessed. Use of screening systems such 
as IMPARTS could revolutionise patient recruitment into trials, using routinely collected patient 
reported outcomes to identify eligible and motivated patients, and allow easy measurement of 
“consent for contact” for research purposes. [39] 
4.1 Limitations 
The data presented here comes from outpatients attending appointments for chronic physical health 
conditions across a range of specialist services. Whilst it is possible that the patients with highest 
levels of physical and mental health needs may not be captured using the in-clinic screening system, 
our results are likely to be more representative of the general outpatient population than research 
relying on traditional research consent procedures, which typically under-represent ethnic minorities 
and individuals from low socioeconomic status, [40] leading to questionable generalisability of 
findings. [41] Pilot data collected in several of these services (rheumatology, limb reconstruction and 
dermatology) suggest that the proportion of patients screened can vary across services (98.2%-
62.5%), depending on the structure of the clinics and resources available.[21] We therefore have no 
information about the mental health and smoking status of the patients who were not screened and 
cannot assess any systematic differences between screened vs. non-screened patients. Moreover, 
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we do not have information on patients who only partially completed screening, and reasons for non-
completion, such as a loss of internet connectivity.  
The self-report of socially undesirable behaviours such as tobacco smoking may be subject to 
reporting bias, particularly in groups of people that are receiving care for smoking-related diseases. 
Estimates based on self-report are usually lower when compared with those established by 
biochemical measures such as salivary or urinary cotinine, however the extent of the difference in 
prevalence estimates of smoking status assessed via self-report or biochemical measures vary by 
study sample and country, with estimates ranging between 0.3% and 4.4% [42-43]. Biochemical 
measures are generally used in research populations rather than routine clinical practice, where 
resource constraints may preclude routine use of biochemical measures.  
The Heaviness of Smoking Index used to assess severity of nicotine dependence is well validated 
in daily smokers, however the validity of this measure has not yet been reported for non-daily 
smokers [44].  The IMPARTS smoking measure does not capture daily vs non-daily smokers and 
therefore the validity of the HSI to indicate nicotine dependence in our sample is unclear.   
Mining health records for research purposes is becoming more common, particularly with increasing 
pressure on research and clinical budgets.[45] However this methodology brings with it limitations 
in the quality of data available. Over 50% of the patients in our dataset had missing ethnicity data, 
due to data omissions from clinical records, spelling and typing errors, as well as inconsistencies in 
coding schemes between hospital sites. Whilst it would be preferable to be able to include 
sociodemographic information such as ethnicity and social deprivation, these data were not 
consistently available and reliably up-to-date. Similarly, the heterogeneous patient groups used in 
this analysis precluded inclusion of disease-related variables such as disease severity or 
comorbidity, which may also have been useful additions to our analysis.  
4.2 Conclusion 
This research has used data collected as part of routine clinical practice to examine the relationships 
between mental and physical comorbidity and smoking. Experiencing depression or anxiety is a risk 
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factor for increased smoking prevalence and nicotine dependence in patients with chronic physical 
health conditions, but are not associated with reduced odds of wanting help with quitting smoking. 
These results have several implications. Common mental disorders are associated with substantially 
worsened longitudinal disease outcomes [32], to which smoking contributes. Patients with common 
mental disorders can have excellent outcomes from smoking cessation therapies, and a general 
hospital encounter represents an opportunity to access patients who may benefit from such 
interventions. 
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Table 1. Description of study sample, and prevalence of pMDD, suicidal ideation, pGAD and smoking. 
    Combined ACHD Dermatology Dialysis LR LT MSK Pain Rheumatology Stroke TYA Cancer 
Total N 
 
7878 667 1613 228 513 178 789 1093 2475 166 156 
Age, M(SD) 
 
44.8 (16.2) 31.6 (13.5) 43.9 (14.6) 55.5 (16.5) 44.8 (14.9) 18.1 (1.7) 43.8 (14.0) 45.8 (12.2) 50.0 (15.6) 62.7 (15.1) 21.7 (2.5) 
Age Category, N(%) <33 years 2032 (25.8) 430 (64.5) 393 (24.4) 23 (10.1) 122 (23.8) 178 (100.0) 195 (24.7) 166 (15.2) 362 (14.6) 7 (4.2) 156 (100.0) 
 33-45 years 2026 (25.7) 131 (19.6) 496 (30.8) 30 (13.2) 145 (28.3) 0 (0.00) 247 (31.3) 348 (31.8) 616 (24.9) 13 (7.8) 0 (0.0) 
 46-55 years 1786 (22.7) 55 (8.3) 375 (23.3) 65 (28.5) 123 (24.0) 0 (0.00) 183 (23.2) 357 (32.7) 595 (24.0) 33 (19.9) 0 (0.0) 
 >55 years 2034 (25.8) 51 (7.7) 349 (21.6) 110 (48.3) 123 (24.0) 0 (0.00) 164 (20.8) 222 (20.3) 902 (36.4) 113 (68.1) 0 (0.0) 
Female Gender, N(%) 4553 (57.8) 336 (50.4) 720 (44.6) 98 (43.0) 134 (26.1) 94 (52.8) 480 (60.9) 736 (67.3) 1806 (73.0) 78 (47.0) 71 (45.5) 
Depression, N(%)^ No Symptoms 4951 (63.2) 577 (86.5) 1166 (72.3) 122 (53.5) 341 (66.6) 132 (66.6) 500 (65.8) 305 (27.9) 1587 (64.3) 127 (76.5) 94 (60.7) 
 
Some Symptoms 1070 (13.7) 62 (9.3) 176 (10.9) 85 (38.3) 73 (14.3) 25 (14.3) 129 (17.0) 130 (11.9) 325 (13.2) 22 (13.3) 43 (27.7) 
 
pMDD 1815 (23.2) 28 (4.2) 271 (16.8) 21 (9.2) 98 (19.1) 18 (10.3) 131 (17.2) 658 (60.2) 555 (22.5) 17 (10.2) 18 (11.6) 
Suicidal Ideation, N(%) 471 (6.1) 7 (1.1) 66 (4.1) 8 (5.2) 27 (5.3) 4 (2.3) 35 (4.6) 160 (14.6) 150 (6.1) 9 (5.4) 5 (3.2) 
Anxiety, N(%)^ No Symptoms 5141 (75.9) 583 (87.4) 1252 (77.6) 168 (73.7) 382 (74.6) 135 (77.1) 596 (75.8) - 1795 (76.7) 130 (78.3) 100 (64.5) 
 
Some Symptoms 381 (5.6) 29 (4.4) 66 (4.1) 36 (14.8) 26 (5.1) 14 (8.0) 36 (4.6) - 122 (4.9) 15 (9.0) 37 (23.9) 
 
pGAD 1250 (18.5) 55 (8.3) 295 (18.3) 24 (10.5) 104 (20.3) 26 (14.9) 154 (19.6) - 553 (22.4) 21 (12.7) 18 (11.6) 
pMDD and pGAD  825 (10.5) 21 (3.2) 200 (12.4) 12 (5.3) 69 (13.5) 11 (6.2) 102 (12.9) - 386 (15.6) 10 (6.0) 14 (9.0) 
Current Smoker, N(%)  1543 (19.6) 71 (10.6) 404 (25.1) 23 (10.1) 108 (21.1) 22 (12.4) 141 (17.9) 314 (28.7) 416 (16.8) 24 (14.5) 20 (12.8) 
HSI, M(SD)^^  1.7 (1.5) 1.0 (1.3) 1.7 (1.4) 1.6 (1.4) 1.6 (1.6) 0.9 (1.3) 1.5 (1.4) 2.1 (1.5) 1.5 (1.4) 1.8 (1.6) 1.0 (1.3) 
Wants help with quitting, N(%)^^ 384 (37.8) 18 (52.9) 99 (34.4 6 (26.1) 25 (48.1) 1 (5.3) 44 (31.2) 78 (44.3) 98 (40.0) 12 (50.0) 3 (23.1) 
ACHD Adult Congenital Heart Disease. LR Limb Reconstruction. LT Liver Transition. MSK Musculoskeletal Physiotherapy. TYA Teenage and Young Adult. MDD Major depressive disorder. 
GAD Generalised anxiety disorder. HSI Heaviness of Smoking Index.  ^ Depression measured in 6505 patients, anxiety measured in 5437.   ^^Asked in 1427 (92.4%) of current smokers.
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Table 2. Logistic regression model showing the relationship between depression, anxiety and suicidal ideation and 
current smoking status, adjusting for and age, gender, and physical condition.  
Variable 
 
OR SE  p 95% CI 
Depression 
 
  <0.001* 
 
 
No symptoms - - - - 
 
Some symptoms 1.46 0.14  1.21, 1.77 
 
pMDD 1.93 0.21  1.56, 2.39 
Anxiety^ 
 
  0.001* 
 
 
No symptoms - - - - 
 
Some symptoms 0.79 0.12  0.58, 1.07 
 
pGAD 1.44 0.15  1.18, 1.76 
Suicidal Ideation No - - - - 
 Yes 1.24 0.18 0.13 0.94, 1.64 
Age 
 
0.98 0.00 <0.001 0.98, 0.99 
Gender Male - - - - 
 
Female 0.75 0.05 <0.001 0.66,0.86 
*p value for trend. ^ Not adjusted for physical condition. pMDD probable Major Depressive Disorder. pGAD probable 
Generalised Anxiety Disorder 
 
Table 3. Linear regression model showing the relationship between depression, anxiety, suicidal ideation and 
nicotine dependence, adjusting for age, gender and physical condition (in current smokers, N=1318). 
Variable   b SE  p 95% CI 
Depression No symptoms - - <0.001* - 
 
Some symptoms 0.24 0.13 
 
-0.01, 0.48 
 
pMDD 0.49 0.13 
 
0.23, 0.75 
Anxiety^ No symptoms - - 0.91* - 
 
Some symptoms 0.02 0.21 
 
-0.39, 0.43 
  pGAD -0.02 0.12   -0.27, 0.22 
Suicidal Ideation No - - - - 
 Yes 0.15 0.17 0.40 -0.19, 0.48 
Age  0.02 0.00 <0.001 0.01, 0.03 
Gender Male - - - - 
 
Female -0.08 0.09 0.38 -0.25, 0.09 
*p value for trend. ^Not adjusted for physical condition. pMDD probable Major Depressive Disorder. pGAD 
probable Generalised Anxiety Disorder 
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Table 4.  Logistic regression model showing the relationship between depression, anxiety, suicidal ideation and  
wanting help with quitting, adjusting for age, gender, and physical health condition (in subset of current smokers, 
N=1015). 
Variable 
 
OR SE  p 95% CI 
Depression 
 
  0.77*  
 
No symptoms - - - - 
 
Some symptoms 1.01 0.22  0.65, 1.55 
 
Probable MDD 0.94 0.22  0.60, 1.48 
Anxiety^ 
 
  0.08* 
 
 
No symptoms - - - - 
 
Some symptoms 1.40 0.47  0.72, 2.72 
 
Probable GAD 1.42 0.30  0.94, 2.16 
Suicidal Ideation No - - - - 
 Yes 1.72 0.50 0.06 0.98, 3.03 
Age 
 
1.00 0.01 0.91 0.99, 1.01 
Gender Male - - - - 
 
Female 0.75 0.11 0.06 0.55, 1.01 
*p value for linear trend. ^not adjusted for physical condition. MDD probable Major Depressive Disorder. 
GAD probable Generalised Anxiety Disorder 
 
